Verona Pharma plc Result Of Agm

 
TIDMVRP 
 
   LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that all resolutions 
proposed at the Annual General Meeting held today were duly passed. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma may also develop ensifentrine for the treatment of cystic 
fibrosis and asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                         Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer              info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
N+1 Singer                                                Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
 Aubrey Powell /Jen Boorer /Iqra Amin (Corporate 
 Finance) Brough Ransom /Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                          Tel: +44 (0) 203 922 0891 
 (European Media and Investor enquiries)                   verona@optimumcomms.com 
Mary Clark, Anne Marieke Ezendam, Hollie Vile

(END) Dow Jones Newswires

May 07, 2019 07:52 ET (11:52 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024